During the 66th ASH Annual Meeting and Exposition, Mehta P. presented results from a post-hoc analysis of the UK NCRI AML19 trial evaluating the efficacy and safety of CPX-351 vs FLAG-Ida.
An acalabrutinib triplet elicited a high response rate in patients with de novo mantle cell lymphoma.
Researchers explored the risks for basal cell carcinoma, squamous cell carcinoma, and melanoma in patients who underwent BMT.
Mansi R. Shah, MD, on the effects of IVIG on infections in recipients of teclistamab therapy for multiple myeloma.
Dostarlimab received breakthrough therapy designation from the FDA for locally advanced dMMR/MSI-H rectal cancer.
The phase 3 randomized controlled trial of extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (PM) (MARS2) reported “extended pleurectomy decortication was…
Treatment with bosutinib led to high response rates with a manageable safety profile in patients with CML who had previously received a TKI.
Pap tests, HPV vaccines, and cervical screenings for women January is Cervical Cancer Awareness Month, and as the new year begins, Fox Chase Cancer Center…
Patients with myelofibrosis who cleared driver mutations within 30 days after hematopoietic stem cell transplantation survived longer and exhibited reduce risk for relapse, according to…
Dr. Pankit Vachhani presents key data from the CYTO-PV and MAJIC-PV studies, evaluating the efficacy of ruxolitinib versus best available therapy in patients with polycythemia…
